Article Data

  • Views 369
  • Dowloads 109

Case Reports

Open Access

Successful pregnancy achieved by in vitro fertilization after fertility-preserving treatments in an infertile woman with borderline ovarian tumor and endometrial complex atypical hyperplasia: a case report

  • Z. Xu1,*,
  • H. Wen1
  • Q. Xue1

1Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing (China)

DOI: 10.31083/j.ejgo.2020.01.4773 Vol.41,Issue 1,February 2020 pp.126-129

Published: 15 February 2020

*Corresponding Author(s): Z. Xu E-mail:


Both borderline ovarian tumors (BOTs) and complex atypical hyperplasia (CAH) are low malignant disease of the female reproductive system, which can be treated with fertility-preserving treatments for women of reproductive age. Assisted reproductive technology (ART) is used to achieve pregnancy in infertile women. Although treatments for the isolated disease have some guidelines, protocol making is not that simple when abnormalities coexist. Here, a case of patient with BOT, a history of CAH, and infertility is presented. After fertility-preserving surgery and in-vitro fertilization and embryo transfer (IVF-ET) , the patient successfully achieved a twin pregnancy leading to term live birth. The treatment process towards the complex situation is available for future reference. Consent: We present the first case with abnormalities co-existence and the process of combined treatment is effective and available for future reference.


Borderline ovarian tumors; Complex atypical hyperplasia; Laparoscopy; Assisted reproductive technology.

Cite and Share

Z. Xu,H. Wen,Q. Xue. Successful pregnancy achieved by in vitro fertilization after fertility-preserving treatments in an infertile woman with borderline ovarian tumor and endometrial complex atypical hyperplasia: a case report. European Journal of Gynaecological Oncology. 2020. 41(1);126-129.


[1] Vasconcelos I., de Sousa Mendes M.: “Conservative surgery in ovarian borderline tumours: a meta-analysis with emphasis on recurrence risk”. Eur. J. Cancer, 2015, 51, 620.

[2] Darai E., Fauvet R., Uzan C., Gouy S., Duvillard P., Morice P.: “Fertility and borderline ovarian tumor: a systematic review of conservative management, risk of recurrence and alternative options”. Hum. Reprod. Update, 2013, 19, 151.

[3] Gunderson C.C., Fader A.N., Carson K.A., Bristow R.E.: “Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review”. Gynecol. Oncol., 2012, 125, 477.

[4] Gallos I.D., Yap J., Rajkhowa M., Luesley D.M., Coomarasamy A., Gupta J.K.: “Regression, relapse, and live birth rates with fertilitysparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis”. Am. J. Obstet. Gynecol., 2012, 207, 266.e1.

[5] Gokcu M., Gungorduk K., Asicioglu O., Cetinkaya N., Gungor T., Pakay G., et al.: “Borderline ovarian tumors: clinical characteristics, management, and outcomes - a multicenter study”. J. Ovarian Res., 2016, 9, 66.

[6] Trimble C.L., Kosary C., Trimble E.L.: “Long-term survival and patterns of care in women with ovarian tumors of low malignant potential”. Gynecol. Oncol., 2002, 86, 34.

[7] Iglesias D.A., Ramirez P.T.: “Role of minimally invasive surgery in staging of ovarian cancer”. Curr. Treat. Options Oncol., 2011, 12, 217.

[8] Siristatidis C., Sergentanis T.N., Kanavidis P., Trivella M., Sotiraki M., Mavromatis I., et al.: “Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer—a systematic review and meta-analysis”. Hum. Reprod. Update, 2013, 19, 105.

[9] Stewart L.M., Holman C.D., Finn J.C., Preen D.B., Hart R.: “In vitro fertilization is associated with an increased risk of borderline ovarian tumours”. Gynecol. Oncol., 2013, 129, 372.

[10] Huusom L.D., Frederiksen K., Hogdall E.V., Glud E., Christensen L., Hogdall C.K., et al.: “Association of reproductive factors, oral contraceptive use and selected lifestyle factors with the risk of ovarian borderline tumors: a Danish case-control study”. Cancer Causes Control, 2006, 17, 821.

[11] Basille C., Olivennes F., Le Calvez J., Beron-Gaillard N., Meduri G., Lhomme C., et al.: “Impact of gonadotrophins and steroid hormones on tumour cells derived from borderline ovarian tumours”. Hum. Reprod., 2006, 21, 3241.

[12] Vasconcelos I., Darb-Esfahani S., Sehouli J.: “Serous and mucinous borderline ovarian tumours: differences in clinical presentation, highrisk histopathological features, and lethal recurrence rates”. BJOG, 2016, 123, 498.

[13] Nam J.H.: ‘Borderline ovarian tumors and fertility”. Curr. Opin. Obstet. Gynecol., 2010, 22, 227.

[14] Lambalk C.B., Banga F.R., Huirne J.A., Toftager M., Pinborg A., Homburg R., et al.: “GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type”. Hum. Reprod. Update, 2017, 23, 560.

[15] Suh-Burgmann E., Hung Y.Y., Armstrong M.A.: “Complex atypical endometrial hyperplasia: the risk of unrecognized adenocarcinoma and value of preoperative dilation and curettage”. Obstet. Gynecol., 2009, 114, 523.

[16] Zhou R., Yang Y., Lu Q., Wang J., Miao Y., Wang S., et al.: “Prognostic factors of oncological and reproductive outcomes in fertilitysparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin in Chinese patients”. Gynecol. Oncol., 2015, 139, 424.

[17] Kudesia R., Singer T., Caputo T.A., Holcomb K.M., Kligman I., Rosenwaks Z., et al.: “Reproductive and oncologic outcomes after progestin therapy for endometrial complex atypical hyperplasia or carcinoma”. Am. J. Obstet. Gynecol., 2014, 210, 255.e1.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time